- 中文名称
Inotuzumab Ozogamicin (CD22) 抗体, 单克隆
- 英文名字
- Inotuzumab Ozogamicin (CD22) Antibody, Monoclonal
- 供应商
- ProSci
- 产品货号
- PSI-10-276
- 产品报价
- ￥询价/0.1mg
- 产品说明书
- 点击查看
- 购买方式
- 银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of fully remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5.
- 应用类型
- 该NALP1 抗体产品相关信息查看ProSci提供得说明书
- 免疫原
- Humanized / CD22 [Homo sapiens]
- 来源宿主
- 该NALP1 抗体产品相关信息查看ProSci提供得说明书
- 反应性
- 该NALP1 抗体产品相关信息查看ProSci提供得说明书
- 保存建议
- Store at -80˚C
- 其他
- ProSci Incorporated于1998年成立于美国加州圣地亚哥市,从事抗体等科研试剂的研发、生产和销售。产品涵盖了细胞凋亡、信号转导、免疫、肿瘤、细胞生物、神经生物、传染病等领域。ProSci拥有超过30000种单克隆抗体和多克隆抗体。ProSci的抗体大都经免疫亲和层析纯化,具有高纯度、高亲和力、特异性强等特点,所有的ProSci抗体都经过了严格的验证测试和质量控制,已保证高质量的产品。此外,ProSci还提供标记二抗,重组蛋白,细胞和组织裂解液,细胞涂片,组织切片,多肽等产品与抗体配套使用。
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
